Posted by Robert Shackelford on January 2, 2019 at 8:28 pm
https://cardinalweekly.com/regen-biopharma-in...for-longs/
Regen BioPharma, Inc. (OTCMKTS:RGBP) Logo
The stock of REGEN BIOPHARMA INC COMMON (OTCMKTS:RGBP) registered a decrease of 17.65% in short interest. RGBP’s total short interest was 18,200 shares in January as published by FINRA. Its down 17.65% from 22,100 shares, reported previously.
The stock increased 10.71% or $0.0003 during the last trading session, reaching $0.0031. About 2.72 million shares traded. Regen BioPharma, Inc. (OTCMKTS:RGBP) has 0.00% since January 2, 2018 and is . It has by 0.00% the S&P500.
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company has market cap of $747,239. It intends to provide various products, including HemaXellerate I, a cellular therapy designed to heal damaged bone marrows; HemaXellerate II, a donor endothelial cell based therapeutic product; dCellVax, a gene silenced dendritic cell immunotherapy for the treatment of breast cancer; and NR2F6, a nuclear receptor cell line. It currently has negative earnings. The firm was founded in 2012 and is based in La Mesa, California.
More recent Regen BioPharma, Inc. (OTCMKTS:RGBP) news were published by: Seekingalpha.com which released: “Regen BioPharma identifies new class of product candidates – Seeking Alpha” on August 30, 2018. Also Seekingalpha.com published the news titled: “Regen Bio on go to start early-stage study of HemaXellerate in aplastic anemia – Seeking Alpha” on December 15, 2015. Seekingalpha.com‘s news article titled: “Regen Bio execs gets 10M-share payouts of preferred stock for resolving HemaXellerate clinical hold – Seeking Alpha” with publication date: April 11, 2016 was also an interesting one.